Cancer Therapy
Combination sorafenib and gemcitabine stabilizes disease in advanced solid tumors
Published in Women's Health Weekly, March 9th, 2006
"With its potent inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways. This study is designed to combine sorafenib and gemcitabine due to their compatibility in preclinical models and nonoverlapping clinical toxicities," scientists writing in the journal Clinical Cancer Research report.
L.L. Siu and colleagues, University of Toronto wrote, "An initial dose-escalation part of the study...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Pregnancy hormones and maternal diet may reduce breast cancer risk in offspring - Cholecystectomy
Bulging midriff roughly doubles women's chances of gallstone surgery - Coronary Artery Disease
Sibling history may identify heart disease risk in women despite low Framingham risk score - Endocrinology
Brain activity confirms that women with low estrogen levels are more sensitive to pain - Adverse Drug Reaction
Etonorgestrel- and levonorgestrel-releasing implants lower ulna bone density - Apoptosis
Cathepsin B and its interacting proteins implicated in apoptosis of ovarian cancer cells - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
